Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
The US Food and Drug Administration on Friday approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients one year of age and older with late-onset Pompe disease. 7 August 2021
UK-based inhaled medicines developer Vectura, which jilted a first offer from the Carlyle Group in July in favor of a bid from tobacco company Philip Morris, today received and accepted a higher bid from the private equity firm. 6 August 2021
Data and analytics company GlobalData has weighed up the factors for consideration surrounding the prevention of thrombosis in managing COVID-19 patients. 6 August 2021
Initial results show the immune response and safety of heterogeneous regimens combining the first component of the Russian Sputnik V vaccine (Sputnik Light vaccine based on human adenovirus serotype 26) and other COVID-19 jabs. 6 August 2021
The UK Competition and Markets Authority (CMA) has provisionally found that US pharma giant Pfizer and its UK distributor Flynn Pharma, abused their dominant positions to overcharge the NHS for vital anti-epilepsy drugs, after reassessing the case. 6 August 2021
German life sciences company Merck KGaA was trading 6% higher in the stock market on Thursday afternoon after presenting a strong set of financial results for the second quarter of 2021. 5 August 2021
Danish diabetes care giant Novo Nordisk’s shares closed up nearly 5% at 611 Danish kroner yesterday, as it reported financials for the first half of 2021, showing that sales increased by 5% in kroner and by 12% at constant exchange ratels (CER) to 66.8 billion kroner $10.65 billion). 5 August 2021
The US Food and Drug Administration’s recent approval of Aduhelm (aducanumab) to treat patients with Alzheimer's disease using the accelerated approval pathway has been questioned and now this is to be investigated by the Office of the Inspector General at the Department of Health and Human Services. 5 August 2021
The US Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Silver Spring, Maryland, in March to select the influenza viruses for the composition of the influenza vaccine for the 2021-2022 US influenza season. 5 August 2021
Patients in the USA with peripheral T-cell lymphoma (PTCL) who have received at least one prior therapy will no longer be given Istodax (romidepsin). 4 August 2021
A major UK trial of cannabis-based drug Sativex in treating the most aggressive form of brain tumor is to launch at 15 National Health Service (NHS) hospitals, following promising results from a Phase I study in 27 patients. 4 August 2021
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Argentina’s Laboratorios Richmond SACIF pharmaceutical company announced the Sputnik V vaccine produced at company’s facilities will become available for vaccination in Argentina starting from this week following successful quality control of test samples at the Gamaleya Center on August 3. 4 August 2021
US drugmaker Eli Lilly saw its revenue rise by 23% in the second quarter of 2021, which amounts to a 12% jump when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. 3 August 2021
ParaPRO, a specialty pharma company focused on innovative anti-parasitic treatments, has announced the availability of Natroba (spinosad) Topical Suspension, 0.9%, the first product for scabies to be approved by the US Food and Drug Administration (FDA) in more than 30 years. 3 August 2021
Following a successful financial year 2020, German family-owned pharma major Boehringer Ingelheim says it has continued its positive trend in the first half of 2021. 3 August 2021
Finnish drugmaker Orion Corp has entered into an agreement to distribute US biopharma firm Marinus Pharmaceuticals’ CNS-selective GABAA modulator, ganaxolone, as a treatment for orphan, genetic disorders ganaxolone, across Europe. 3 August 2021
Ukraine may become one of the European centers for clinical trials and studies of original Western drugs in years to come, according to recent statements by some leading local state officials and the Ukraine media reports. 3 August 2021
Privately-held FluGen, a clinical-stage US vaccine developer, today announced the publication of results from its Phase II human challenge study of Bris2007 M2SR, the company’s investigational, supra-seasonal, live, single-replication, intranasal influenza (flu) vaccine. 2 August 2021